Success Metrics

Active Trials
6(86%)

Phase Distribution

Ph phase_4
5
71%
Ph phase_3
1
14%

Phase Distribution

0

Early Stage

0

Mid Stage

6

Late Stage

Phase Distribution6 total trials
Phase 3Large-scale testing
1(16.7%)
Phase 4Post-market surveillance
5(83.3%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

0.0%

0 of 0 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

6

trials recruiting

Total Trials

7

all time

Status Distribution
Active(7)

Detailed Status

Recruiting4
Active, not recruiting2
Not yet recruiting1

Development Timeline

Analytics

Development Status

Total Trials
7
Active
6
Success Rate
N/A
Most Advanced
Phase 4

Trials by Phase

Phase 31 (16.7%)
Phase 45 (83.3%)

Trials by Status

not_yet_recruiting114%
active_not_recruiting229%
recruiting457%

Recent Activity

6 active trials
Showing 5 of 7
recruitingphase_4

Enavogliflozin vs. Pioglitazone on Glucose and Atherosclerosis

NCT06399835
active_not_recruitingphase_3

Enavogliflozin Outcome Trial in Functional Tricuspid Regurgitation

NCT06027307
recruitingphase_4

ENAVOgliflozin Outcome Trial in Patients With Severe Aortic Stenosis After Transcatheter Aortic Valve Replacement

NCT05672836
active_not_recruiting

To Evaluate the Efficacy and Safety of Envlo Tablet or Envlomet SR Tablet in Patients With Type II Diabetes Mellitus

NCT05926414
recruitingphase_4

Effects of Enavogliflozin on Coronary Microvascular and Cardiac Function in Obesity

NCT06782139
View all 7 trials

Clinical Trials (7)

Showing 7 of 7 trials
NCT06399835Phase 4

Enavogliflozin vs. Pioglitazone on Glucose and Atherosclerosis

Recruiting
NCT06027307Phase 3

Enavogliflozin Outcome Trial in Functional Tricuspid Regurgitation

Active Not Recruiting
NCT05672836Phase 4

ENAVOgliflozin Outcome Trial in Patients With Severe Aortic Stenosis After Transcatheter Aortic Valve Replacement

Recruiting
NCT05926414

To Evaluate the Efficacy and Safety of Envlo Tablet or Envlomet SR Tablet in Patients With Type II Diabetes Mellitus

Active Not Recruiting
NCT06782139Phase 4

Effects of Enavogliflozin on Coronary Microvascular and Cardiac Function in Obesity

Recruiting
NCT06642623Phase 4

A Prospective Trial of Enavogliflozin to Evaluate Cardio-renal Outcome in Type 2 Diabetes Mellitus Patients

Recruiting
NCT06528262Phase 4

Effect of Enavogliflozin on Recurrence of Atrial Fibrillation After Catheter Ablation

Not Yet Recruiting

All 7 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
7